A clinical pathway for community-acquired pneumonia: An observational cohort study

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Frei, Christopher R ^a,b   Bell, Allison M ^a,b   Traugott, Kristi A ^a,b,c   Jaso, Terry C ^a,d   Daniels, Kelly R ^a,b,e   Mortensen, Eric M ^b   Restrepo, Marcos I ^b   Oramasionwu, Christine U ^a,b   Ruiz, Andres D ^a,b,e   Mylchreest, William R ^d   Sikirica, Vanja ^f   Raut, Monika R ^f   Fisher, Alan ^f   Schein, Jeff R ^f  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d SETON FAMILY OF HOSPITALS   (United States)

^e Oakdell Pharmacy Inc   (United States)

^f Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; SURVIVAL; SURVIVAL TIME; UNITED STATES; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; ECONOMICS; HOSPITAL COST; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTOR; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITAL COSTS; HUMANS; LEAST-SQUARES ANALYSIS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; REGRESSION ANALYSIS; RISK FACTORS; TEXAS;

EID: 79959881170     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-188     Document Type: Article

References (26)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
2. Conte JE, Golden JA, McIver M, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 2006, 28:114-21. 10.1016/j.ijantimicag.2006.03.022, 16837169.
3. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003, 37:1405-33. 10.1086/380488, 14614663.
4. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-50. 10.1056/NEJM199701233360402, 8995086.
5. Guven GS, Uzun O. Principles of good use of antibiotics in hospitals. J Hosp Infect 2003, 53:91-6. 10.1053/jhin.2002.1353, 12586566.
6. Restrepo MI, Frei CR. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia. Am J Med 2010, 123:S39-46. 10.1016/j.amjmed.2010.02.005, 20350634.
7. Owens RC, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 2009, 66:S23-30. 10.2146/090087d, 19502225.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. 10.1086/516284, 9455502.
9. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-81. 187901, 8517694.
10. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279:125-9. 10.1001/jama.279.2.125, 9440662.
11. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45:2793-7. 10.1128/AAC.45.10.2793-2797.2001, 90733, 11557471.
12. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002, 44:43-9. 10.1016/S0732-8893(02)00417-0, 12376030.
13. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003, 37:752-60. 10.1086/377539, 12955634.
14. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006, 100:2129-36. 10.1016/j.rmed.2006.03.019, 16730170.
15. Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or = 65 years with community-acquired pneumonia. Clin Ther 2005, 27:1251-9. 10.1016/S0149-2918(05)80214-0, 16199249.
16. File TM, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004, 20:1473-81. 10.1185/030079904X2556, 15383197.
17. Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006, 22:1997-2006. 10.1185/030079906X132505, 17022859.
18. Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001, 95:553-64. 10.1053/rmed.2001.1113, 11453311.
19. Rubio FG, Cunha CA, Lundgren FL, et al. Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial. Braz J Infect Dis 2008, 12:202-9. 10.1590/S1413-86702008000300008, 18833404.
20. Tamm M, Todisco T, Feldman C, et al. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect 2007, 13:162-71.
21. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002, 24:1292-308. 10.1016/S0149-2918(02)80034-0, 12240780.
22. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001, 18(Suppl 1):S17-23.
23. Noreddin AM, El-Khatib WF, Aolie J, Salem AH, Zhanel GG. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae. Int J Infect Dis 2009, 13:483-7. 10.1016/j.ijid.2008.08.016, 19046911.
24. Malone DC, Shaban HM. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother 2001, 35:1180-5.
25. Reyes Calzada S, Martinez Tomas R, Cremades Romero MJ, Martinez Moragon E, Soler Cataluna JJ, Menendez Villanueva R. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med 2007, 101:1909-15. 10.1016/j.rmed.2007.04.018, 17628462.
26. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008, 168:2205-10. 10.1001/archinte.168.20.2205, 19001196.